Clinical trials: Acquired Ptosis
Blepharoptosis
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.
- Trial name
- NCT01848041
- Testing
- RVL-1201
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Blepharoptosis
A Study in Chinese Patients With Acquired Blepharoptosis
This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis.
- Trial name
- NCT06683651
- Testing
- STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800
- Where
- 23 sites in China
- Volunteers
- 180 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Acquired Blepharophimosis
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
- Trial name
- NCT06514612
- Testing
- STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
- Where
- 36 sites in Czechia, France and 7 more
- Volunteers
- 234 people
- Sponsor
- Santen SAS
Acquired Blepharoptosis
LEV102 Topical Gel in Acquired Blepharoptosis
Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.
- Trial name
- NCT05715346
- Testing
- LEV102 1.0%, LEV102 2.0%, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Levation Pharma, Ltd.
Blepharoptosis
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
- Trial name
- NCT03536949
- Testing
- RVL-1201, Vehicle ophthalmic solution
- Where
- 35 sites in United States
- Volunteers
- 234 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Acquired Blepharoptosis
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an…
- Trial name
- NCT02436759
- Testing
- RVL-1201
- Where
- 14 sites in United States
- Volunteers
- 140 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Blepharoptosis
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
- Trial name
- NCT03565887
- Testing
- RVL-1201, Vehicle ophthalmic solution
- Where
- 36 sites in United States
- Volunteers
- 164 people
- Sponsor
- RVL Pharmaceuticals, Inc.